ga

Skip to content

My Files [0]

These are the files you have added to your collection.

  • You don't have any documents yet, feel free to browse the website and add documents.

CADTH » Search All Products » Common Drug Review

Common Drug Review

Results 1 - 248 of 248

  1. Abacavir / lamivudine

    Brand name Kivexa
    Manufacturer GlaxoSmithKline
    Indication HIV infection
    Submission type Initial
    Project Number S0038
    Date submission received 2005-07-26
    Status Complete Submission status report
    Date recommendation issued 2005-12-07 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  2. Abatacept

    Brand name Orencia
    Manufacturer Bristol-Myers Squibb Canada
    Indication Arthritis, Rheumatoid
    Submission type Resubmission #1
    Project Number S0187
    Date submission received 2009-12-02
    Status Complete Submission status report
    Date recommendation issued 2010-06-17 Recommendation and reasons
    Recommendation List in a similar manner

  3. Abatacept

    Brand name Orencia
    Manufacturer Bristol-Myers Squibb Canada
    Indication Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid
    Submission type New Indication
    Project Number S0145
    Date submission received 2008-08-29
    Status Complete Submission status report
    Date recommendation issued 2009-04-22 Recommendation and reasons
    Recommendation List with criteria/condition

  4. Abatacept

    Brand name Orencia
    Manufacturer Bristol-Myers Squibb Canada
    Indication Arthritis, Rheumatoid
    Submission type Initial
    Project Number S0084
    Date submission received 2006-10-26
    Status Complete Submission status report
    Date recommendation issued 2007-06-27 Recommendation and reasons
    Recommendation List with criteria/condition

  5. Acamprosate calcium

    Brand name Campral
    Manufacturer Prempharm Inc.
    Indication Alcohol Abstinence
    Submission type Request for Advice
    Project Number S0143
    Date submission received 2008-07-22
    Status Complete Submission status report
    Recommendation

  6. Acamprosate calcium

    Brand name Campral
    Manufacturer Prempharm Inc.
    Indication Alcohol Abstinence
    Submission type Initial
    Project Number S0108
    Date submission received 2007-08-29
    Status Complete Submission status report
    Date recommendation issued 2008-03-27 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

  7. Adalimumab

    Brand name Humira
    Manufacturer Abbott Laboratories, Limited
    Indication Psoriasis
    Submission type New Indication
    Project Number S0130
    Date submission received 2008-04-15
    Status Complete Submission status report
    Date recommendation issued 2008-10-16 Recommendation and reasons
    Recommendation List with criteria/condition

  8. Adalimumab

    Brand name Humira
    Manufacturer Abbott Laboratories, Limited
    Indication Crohn's disease
    Submission type Resubmission #3
    Project Number S0105
    Date submission received 2007-07-12
    Status Complete Submission status report
    Date recommendation issued 2007-12-19 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

  9. Adalimumab

    Brand name Humira
    Manufacturer Abbott Laboratories, Limited
    Indication Ankylosing spondylitis (AS)
    Submission type Resubmission #2
    Project Number S0087
    Date submission received 2006-11-17
    Status Complete Submission status report
    Date recommendation issued 2007-06-27 Recommendation and reasons
    Recommendation List with criteria/condition

  10. Adalimumab

    Brand name Humira
    Manufacturer Abbott Laboratories Limited
    Indication Arthritis, psoriatic
    Submission type Resubmission #1
    Project Number S0066
    Date submission received 2006-06-21
    Status Complete Submission status report
    Date recommendation issued 2006-11-29 Recommendation and reasons
    Recommendation List with criteria/condition

  11. Adalimumab

    Brand name Humira
    Manufacturer Abbott Laboratories Limited
    Indication Arthritis, rheumatoid
    Submission type Initial
    Project Number S0022
    Date submission received 2004-09-24
    Status Complete Submission status report
    Date recommendation issued 2005-02-11 Recommendation and reasons
    Recommendation List with criteria/condition

  12. Adefovir dipivoxil

    Brand name Hepsera
    Manufacturer gilead Sciences Canada Inc.
    Indication Hepatitis B
    Submission type Request for Advice
    Project Number S0103
    Date submission received 2007-06-29
    Status Complete Submission status report
    Date recommendation issued 2007-10-18 Recommendation and reasons
    Recommendation List with criteria/condition

  13. Adefovir dipivoxil

    Brand name Hepsera
    Manufacturer Gilead Sciences Canada Inc.
    Indication Hepatitis B
    Submission type Initial
    Project Number S0060
    Date submission received 2006-04-24
    Status Complete Submission status report
    Date recommendation issued 2006-11-29 Recommendation and reasons
    Recommendation Do not list

  14. Agalsidase alfa

    Brand name Replagal
    Manufacturer Transkaryotic Therapies Inc.
    Indication Fabry Disease
    Submission type Initial
    Project Number S0006
    Date submission received 2004-02-19
    Status Complete Submission status report
    Date recommendation issued 2004-11-24 Recommendation and reasons
    Recommendation Do not list

  15. Agalsidase beta

    Brand name Fabrazyme
    Manufacturer Genzyme Canada
    Indication Fabry Disease
    Submission type Resubmission #1
    Project Number S0028
    Date submission received 2004-12-10
    Status Complete Submission status report
    Date recommendation issued 2005-05-18 Recommendation and reasons
    Recommendation Do not list

  16. Agalsidase beta

    Brand name Fabrazyme
    Manufacturer Genzyme Canada
    Indication Fabry Disease
    Submission type Initial
    Project Number S0007
    Date submission received 2004-02-24
    Status Complete Submission status report
    Date recommendation issued 2004-11-24 Recommendation and reasons
    Recommendation Do not list

  17. Alefacept

    Brand name Amevive
    Manufacturer Biogen Idec Canada Inc.
    Indication Psoriasis, moderate to severe chronic plaque
    Submission type Resubmission #1
    Project Number S0053
    Date submission received 2006-02-28
    Status Complete Submission status report
    Date recommendation issued 2006-09-27 Recommendation and reasons
    Recommendation Do not list

  18. Alefacept

    Brand name Amevive
    Manufacturer Biogen Idec Canada Inc.
    Indication Psoriasis, moderate to severe chronic plaque
    Submission type Initial
    Project Number S0024
    Date submission received 2004-11-16
    Status Complete Submission status report
    Date recommendation issued 2005-05-26 Recommendation and reasons
    Recommendation Do not list

  19. Alendronate sodium / cholecalciferol

    Brand name Fosavance 70/5600
    Manufacturer Merck Frosst Canda Ltd.
    Indication Osteoporosis
    Submission type Initial
    Project Number S0153
    Date submission received 2008-12-18
    Status Complete Submission status report
    Date recommendation issued 2009-06-17 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  20. Alendronate sodium / cholecalciferol

    Brand name Fosavance
    Manufacturer Merck Frosst Canda Ltd.
    Indication Osteoporosis
    Submission type Initial
    Project Number S0059
    Date submission received 2006-03-27
    Status Complete Submission status report
    Date recommendation issued 2006-09-27 Recommendation and reasons
    Recommendation Do not list

  21. Alglucosidase

    Brand name Myozyme
    Manufacturer Genzyme Canada Inc.
    Indication Pompe’s disease
    Submission type Initial
    Project Number S0080
    Date submission received 2006-10-10
    Status Complete Submission status report
    Date recommendation issued 2007-06-14 Recommendation and reasons
    Recommendation List with criteria/condition

  22. Aliskiren

    Brand name Rasilez
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Hypertension
    Submission type Initial
    Project Number S0118
    Date submission received 2007-11-30
    Status Complete Submission status report
    Date recommendation issued 2008-06-25 Recommendation and reasons
    Recommendation Do not list

  23. Alitretinoin

    Brand name Toctino
    Manufacturer Actelion
    Indication Eczema
    Submission type Initial
    Project Number S0232
    Date submission received 2011-05-09
    Patient input deadline 2011-05-30
    Status Complete Submission status report
    Date recommendation issued 2011-10-24 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

  24. Almotriptan

    Brand name Axert
    Manufacturer Janssen-Ortho Inc.
    Indication Migraine
    Submission type Initial
    Project Number S0005
    Date submission received 2003-12-24
    Status Complete Submission status report
    Date recommendation issued 2004-05-27 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  25. Ambrisentan

    Brand name Volibris
    Manufacturer GlaxoSmithKline Inc.
    Indication Pulmonary arterial hypertension (WHO class II and III)
    Submission type Initial
    Project Number S0142
    Date submission received 2008-07-09
    Status Complete Submission status report
    Date recommendation issued 2008-12-17 Recommendation and reasons
    Recommendation List with criteria/condition

  26. Amlodipine besylate / atorvastatin calcium

    Brand name Caduet
    Manufacturer Pfizer Canada Inc.
    Indication Hypertension/ Dyslipidemia
    Submission type Initial
    Project Number S0048
    Date submission received 2005-12-15
    Status Complete Submission status report
    Date recommendation issued 2006-05-17 Recommendation and reasons
    Recommendation List with criteria/condition

  27. Apixaban

    Brand name Eliquis
    Manufacturer Bristol-Myers Squibb and Pfizer Canada Alliance
    Indication prevention of venous thromboembolic events
    Submission type Initial
    Project Number S0264
    Date submission received 2011-12-19
    Patient input deadline 2012-01-17
    Status Active Submission status report
    Recommendation

  28. Aprepitant

    Brand name Emend
    Manufacturer Merck Frosst Canada Ltd.
    Indication Chemotherapy induced Nausea and Vomiting
    Submission type Initial
    Project Number S0109
    Date submission received 2007-08-29
    Status Complete Submission status report
    Date recommendation issued 2008-02-20 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

  29. Aripiprazole

    Brand name Abilify
    Manufacturer Bristol-Myers Squibb
    Indication Schizophrenia and Related Psychotic Disorders
    Submission type Request for Advice
    Project Number S0226
    Date submission received 2011-03-29
    Status Complete Submission status report
    Date recommendation issued 2011-07-18 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

  30. Aripiprazole

    Brand name Abilify
    Manufacturer Bristol-Myers Squibb Canada
    Indication Schizophrenia
    Submission type Initial
    Project Number S0183
    Date submission received 2009-11-06
    Status Complete Submission status report
    Date recommendation issued 2010-04-27 Recommendation and reasons
    Recommendation Do not list

  31. Asenapine

    Brand name Saphris
    Manufacturer Lundbeck Canada Inc.
    Indication Bipolar 1 and schizophrenia
    Submission type Initial
    Project Number S0262
    Date submission received 2011-12-02
    Patient input deadline 2012-01-09
    Status Active Submission status report
    Recommendation

  32. Atazanavir

    Brand name Reyataz
    Manufacturer Bristol Myers Squibb
    Indication HIV infection
    Submission type Initial
    Project Number S0002
    Date submission received 2003-12-16
    Status Complete Submission status report
    Date recommendation issued 2004-05-27 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  33. Atomoxetine hydrochloride

    Brand name Strattera
    Manufacturer Eli Lilly Canada Inc.
    Indication Attention deficit hyperactivity disorder
    Submission type Request for Advice
    Project Number S0085
    Date submission received 2006-09-25
    Status Complete Submission status report
    Recommendation

  34. Atomoxetine hydrochloride

    Brand name Strattera
    Manufacturer Eli Lilly Canada Inc.
    Indication Attention deficit hyperactivity disorder
    Submission type Initial
    Project Number S0031
    Date submission received 2005-01-25
    Status Complete Submission status report
    Date recommendation issued 2005-09-28 Recommendation and reasons
    Recommendation Do not list

  35. Azelaic acid

    Brand name Finacea
    Manufacturer Bayer Inc.
    Indication Rosacea
    Submission type Initial
    Project Number S0209
    Date submission received 2010-08-31
    Patient input deadline 2010-09-22
    Status Complete Submission status report
    Date recommendation issued 2011-02-16 Recommendation and reasons
    Recommendation List
    Plain language recommendation Plain language recommendation

  36. Aztreonam for Inhalation Solution

    Brand name Cayston
    Manufacturer Gilead Sciences Canada Inc.
    Indication Cystic fibrosis (CF) with chronic pulmonary pseudomonas aeruginosa infections
    Submission type Initial
    Project Number S0220
    Date submission received 2010-11-26
    Patient input deadline 2011-01-31
    Status Complete Submission status report
    Date recommendation issued 2011-07-18 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

  37. Belimumab

    Brand name Benlysta
    Manufacturer GlaxoSmithKline Inc.
    Indication Systemic Lupus Erythematosus
    Submission type Initial
    Project Number S0251
    Date submission received 2011-08-30
    Patient input deadline 2011-10-11
    Status Active Submission status report
    Recommendation

  38. Boceprevir

    Brand name Victrelis
    Manufacturer Merck Canada Inc.
    Indication Hepatitis C, chronic
    Submission type Pre-NOC
    Project Number S0231
    Date submission received 2011-05-26
    Patient input deadline 2011-06-30
    Status Complete Submission status report
    Date recommendation issued 2011-10-24 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

  39. Brimonidine tartrate / timolol maleate

    Brand name Combigan Ophthalmic Solution
    Manufacturer Allergan Canada Inc.
    Indication Glaucoma
    Submission type Initial
    Project Number S0001
    Date submission received 2003-12-15
    Status Complete Submission status report
    Date recommendation issued 2004-05-27 Recommendation and reasons
    Recommendation List with criteria/condition

  40. Brinzolamide and timolol maleate suspension

    Brand name Azarga
    Manufacturer Alcon Canada Inc.
    Indication Glaucoma and Ocular hypertension
    Submission type Initial
    Project Number S0173
    Date submission received 2009-08-28
    Status Complete Submission status report
    Date recommendation issued 2010-02-18 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  41. Buprenorphine transdermal patch

    Brand name BuTrans
    Manufacturer Purdue Pharma
    Indication Pain, persistent (moderate intensity)
    Submission type Resubmission #1
    Project Number S0233
    Date submission received 2011-05-09
    Patient input deadline 2011-05-11
    Status Complete Submission status report
    Date recommendation issued 2011-09-28 Recommendation and reasons
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

  42. Buprenorphine transdermal patch

    Brand name BuTrans
    Manufacturer Purdue Pharma
    Indication Pain, persistent (moderate intensity)
    Submission type Initial
    Project Number S0211
    Date submission received 2010-10-19
    Patient input deadline 2010-11-05
    Status Stopped Submission status report
    Recommendation

  43. Buprenorphine / naloxone

    Brand name Suboxone
    Manufacturer Schering-Plough Canada Inc
    Indication Opioid drug dependence (Substitution treatment)
    Submission type Initial
    Project Number S0128
    Date submission received 2008-03-06
    Status Complete Submission status report
    Date recommendation issued 2008-09-24 Recommendation and reasons
    Recommendation List with criteria/condition

  44. Butoconazole nitrate

    Brand name Gynazole.1
    Manufacturer Ferring Pharmaceuticals
    Indication Vaginal infection
    Submission type Initial
    Project Number S0017
    Date submission received 2004-06-30
    Status Complete Submission status report
    Date recommendation issued 2005-01-26 Recommendation and reasons
    Recommendation Do not list

  45. Calcitriol

    Brand name Silkis
    Manufacturer Galderma Canada Inc.
    Indication Psoriasis, mild to moderate plaque
    Submission type Initial
    Project Number S0199
    Date submission received 2010-03-15
    Status Complete Submission status report
    Date recommendation issued 2010-09-22 Recommendation and reasons
    Recommendation Do not list

  46. Canakinumab

    Brand name Ilaris
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Cryopyrin-Associated Periodic Syndrome (CAPS)
    Submission type Initial
    Project Number S0204
    Date submission received 2010-06-30
    Patient input deadline 2010-07-28
    Status Complete Submission status report
    Date recommendation issued 2011-01-26 Recommendation and reasons
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

  47. Carbidopa, levodopa and entacapone

    Brand name Stalevo
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Parkinsons Disease
    Submission type Initial
    Project Number S0131
    Date submission received 2008-04-15
    Status Complete Submission status report
    Date recommendation issued 2008-10-16 Recommendation and reasons
    Recommendation List in a similar manner

  48. Certolizumab pegol

    Brand name Cimzia
    Manufacturer UCB Pharma Canada Inc.
    Indication Arthritis, rheumatoid
    Submission type Initial
    Project Number S0175
    Date submission received 2009-09-03
    Status Complete Submission status report
    Date recommendation issued 2010-05-27 Recommendation and reasons
    Recommendation Do not list

  49. Ciclesonide

    Brand name Alvesco
    Manufacturer Altana Pharma Inc.
    Indication asthma
    Submission type Initial
    Project Number S0074
    Date submission received 2006-07-24
    Status Complete Submission status report
    Date recommendation issued 2006-12-20 Recommendation and reasons
    Recommendation List

  50. Ciclesonide nasal spray

    Brand name Omnaris
    Manufacturer Nycomed Canada Inc.
    Indication Allergic Rhinitis (seasonal and perennial)
    Submission type Initial
    Project Number S0137
    Date submission received 2008-05-07
    Status Complete Submission status report
    Date recommendation issued 2008-11-12 Recommendation and reasons
    Recommendation Do not list

  51. Cinacalcet hydrochloride

    Brand name Sensipar
    Manufacturer Amgen Canada Inc.
    Indication Secondary hyper-parathyroidism in chronic kidney disease
    Submission type Initial
    Project Number S0018
    Date submission received 2004-08-20
    Status Complete Submission status report
    Date recommendation issued 2005-03-23 Recommendation and reasons
    Recommendation Do not list

  52. Ciprofloxacin hydrochloride & dexamethasone otic suspension

    Brand name Ciprodex
    Manufacturer Alcon Canada Inc.
    Indication Otitis media with otorrhea & otitis externa, acute
    Submission type Request for Advice
    Project Number S0101
    Date submission received 2007-06-15
    Status Complete Submission status report
    Date recommendation issued 2007-10-18 Recommendation and reasons
    Recommendation List with criteria/condition

  53. Ciprofloxacin hydrochloride and dexamethasone otic suspension

    Brand name Ciprodex
    Manufacturer Alcon Canada Inc.
    Indication Otitis media with otorrhea & otitis externa, acute
    Submission type Initial
    Project Number S0014
    Date submission received 2004-06-11
    Status Complete Submission status report
    Date recommendation issued 2005-01-26 Recommendation and reasons
    Recommendation Do not list

  54. Clostridium botulinum neurotoxin type A, free from complexing proteins

    Brand name Xeomin
    Manufacturer Merz Pharmaceuticals GmbH
    Indication Post-stroke Spasticity
    Submission type Initial
    Project Number S0193
    Date submission received 2009-06-12
    Status Complete Submission status report
    Date recommendation issued 2009-12-16 Recommendation and reasons
    Recommendation Do not list

  55. Clostridium botulinum neurotoxin type A, free from complexing proteins

    Brand name Xeomin
    Manufacturer Merz Pharmaceuticals GmbH
    Indication Blepharospasm
    Submission type Initial
    Project Number S0168
    Date submission received 2009-06-12
    Status Complete Submission status report
    Date recommendation issued 2009-12-16 Recommendation and reasons
    Recommendation List in a similar manner

  56. Clostridium botulinum neurotoxin type A, free from complexing proteins

    Brand name Xeomin
    Manufacturer Merz Pharmaceuticals GmbH
    Indication Cervical Dystonia
    Submission type Initial
    Project Number S0192
    Date submission received 2009-06-12
    Status Complete Submission status report
    Date recommendation issued 2009-12-16 Recommendation and reasons
    Recommendation List in a similar manner

  57. Cyclosporine

    Brand name Restasis ophthalmic emulsion
    Manufacturer Allergan Inc.
    Indication Moderate to moderately severe dry eye disease
    Submission type Initial
    Project Number S0222
    Date submission received 2010-12-02
    Patient input deadline 2011-02-07
    Status Complete Submission status report
    Date recommendation issued 2011-07-18 Recommendation and reasons
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

  58. Dabigatran etexilate

    Brand name Pradax
    Manufacturer Boehringer Ingelheim
    Indication Prevention of stroke and systemic embolism in patients with atrial fibrillation
    Submission type New Indication
    Project Number S0214
    Date submission received 2010-10-29
    Patient input deadline 2010-11-18
    Status Complete Submission status report
    Date recommendation issued 2011-06-22 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

  59. Dabigatran etexilate

    Brand name Pradax
    Manufacturer Boehringer-Ingelheim (Canada) Ltd.
    Indication Prevention of stroke, systemic embolism and reduction of vascular mortality in patients with atrial fibrillation
    Submission type Pre-NOC - New Indication
    Project Number S0202
    Date submission received 2010-06-04
    Patient input deadline 2010-06-25
    Status Rejected Submission status report
    Recommendation

  60. Dabigatran etexilate

    Brand name Pradax
    Manufacturer Boehringer Ingelheim (Canada) Ltd.
    Indication Venous thromboembolism prevention
    Submission type Initial
    Project Number S0140
    Date submission received 2008-07-08
    Status Complete Submission status report
    Date recommendation issued 2009-01-28 Recommendation and reasons
    Recommendation Do not list

  61. Daptomycin

    Brand name Cubicin
    Manufacturer Cubist Pharmaceuticals Inc.
    Indication Skin and Skin Structure Infections & Bacteremia
    Submission type Initial
    Project Number S0127
    Date submission received 2008-03-06
    Status Complete Submission status report
    Date recommendation issued 2008-09-24 Recommendation and reasons
    Recommendation Do not list

  62. Darifenacin hydrobromide

    Brand name Enablex
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Bladder, overactive
    Submission type Resubmission #1
    Project Number S0147
    Date submission received 2008-10-01
    Status Complete Submission status report
    Date recommendation issued 2009-04-16 Recommendation and reasons
    Recommendation List with criteria/condition

  63. Darifenacin hydrobromide

    Brand name Enablex
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Bladder, overactive
    Submission type Initial
    Project Number S0061
    Date submission received 2006-04-26
    Status Complete Submission status report
    Date recommendation issued 2006-10-19 Recommendation and reasons
    Recommendation Do not list

  64. Darunavir

    Brand name Prezista
    Manufacturer Janssen-Ortho Inc.
    Indication HIV infection (Pediatric)
    Submission type New Indication
    Project Number S0194
    Date submission received 2009-12-22
    Status Complete Submission status report
    Date recommendation issued 2010-06-17 Recommendation and reasons
    Recommendation List with criteria/condition

  65. Darunavir

    Brand name Prezista
    Manufacturer Janssen-Ortho Inc.
    Indication HIV - treatment naive
    Submission type New Indication
    Project Number S0163
    Date submission received 2009-03-27
    Status Complete Submission status report
    Date recommendation issued 2009-10-14 Recommendation and reasons
    Recommendation List with criteria/condition

  66. Darunavir

    Brand name Prezista
    Manufacturer Janssen-Ortho Inc.
    Indication HIV infection
    Submission type Initial
    Project Number S0072
    Date submission received 2006-08-29
    Status Complete Submission status report
    Date recommendation issued 2007-02-14 Recommendation and reasons
    Recommendation List with criteria/condition

  67. Deferasirox

    Brand name Exjade
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Iron overload
    Submission type Initial
    Project Number S0081
    Date submission received 2006-10-26
    Status Complete Submission status report
    Date recommendation issued 2007-04-19 Recommendation and reasons
    Recommendation List with criteria/condition

  68. Delta-9-tetrahydrocannabinol / cannabidiol

    Brand name Sativex
    Manufacturer GW Pharma Ltd.
    Indication Cancer Pain (adjunctive analgesia to maximum tolerated strong opioids)
    Submission type Resubmission #1
    Project Number S0106
    Date submission received 2007-08-07
    Status Complete Submission status report
    Date recommendation issued 2008-02-20 Recommendation and reasons
    Recommendation Do not list

  69. Delta-9-tetrahydrocannabinol / cannabidiol

    Brand name Sativex
    Manufacturer GW Pharma Ltd.
    Indication Neuropathic pain (adjunctive) in MS.
    Submission type Initial
    Project Number S0092
    Date submission received 2007-02-27
    Status Complete Submission status report
    Date recommendation issued 2007-09-26 Recommendation and reasons
    Recommendation Do not list

  70. Denosumab

    Brand name XGEVA
    Manufacturer Amgen Canada Inc.
    Indication Prevention of skeletal-related events due to bone metastases from solid tumours
    Submission type New Indication
    Project Number S0235
    Date submission received 2011-05-27
    Patient input deadline 2011-06-24
    Status Complete Submission status report
    Date recommendation issued 2011-11-16 Recommendation and reasons
    Recommendation List with criteria/condition

  71. Denosumab

    Brand name Prolia
    Manufacturer Amgen Canada Inc.
    Indication Osteoporosis, postmenopausal
    Submission type Initial
    Project Number S0208
    Date submission received 2010-08-13
    Patient input deadline 2010-09-17
    Status Complete Submission status report
    Date recommendation issued 2011-03-30 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

  72. Desvenlafaxine succinate

    Brand name Pristiq
    Manufacturer Wyeth Canada
    Indication Major Depressive Disorder (MDD)
    Submission type Initial
    Project Number S0159
    Date submission received 2009-03-05
    Status Complete Submission status report
    Date recommendation issued 2009-09-23 Recommendation and reasons
    Recommendation Do not list

  73. Dexamethasone Intravitreal Implant

    Brand name Ozurdex
    Manufacturer Allergan
    Indication Macular edema following CRVO
    Submission type Initial
    Project Number S0247
    Date submission received 2011-08-19
    Patient input deadline 2011-09-23
    Status Active Submission status report
    Recommendation

  74. Dienogest

    Brand name Visanne
    Manufacturer Bayer Inc.
    Indication Pelvic pain associated with endometriosis
    Submission type Initial
    Project Number S0255
    Date submission received 2011-10-18
    Patient input deadline 2011-11-08
    Status Active Submission status report
    Recommendation

  75. Dronedarone hydrochloride

    Brand name Multaq
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication Atrial fibrillation
    Submission type Initial
    Project Number S0177
    Date submission received 2009-09-18
    Status Complete Submission status report
    Date recommendation issued 2010-05-27 Recommendation and reasons
    Recommendation Do not list

  76. Drospirenone / ethinyl estradiol

    Brand name Yasmin
    Manufacturer Berlex Canada Inc.
    Indication Contraceptive, oral
    Submission type Initial
    Project Number S0029
    Date submission received 2005-01-20
    Status Complete Submission status report
    Date recommendation issued 2005-06-16 Recommendation and reasons
    Recommendation List

  77. Duloxetine hydrochloride

    Brand name Cymbalta
    Manufacturer Eli Lilly Canada Inc.
    Indication Neuropathic pain, Diabetic
    Submission type Initial
    Project Number S0126
    Date submission received 2008-02-08
    Status Complete Submission status report
    Date recommendation issued 2008-08-14 Recommendation and reasons
    Recommendation List with criteria/condition

  78. Duloxetine hydrochloride

    Brand name Cymbalta
    Manufacturer Eli Lilly Canada Inc.
    Indication Major Depressive Disorder (MDD)
    Submission type Initial
    Project Number S0125
    Date submission received 2008-02-08
    Status Complete Submission status report
    Date recommendation issued 2008-08-14 Recommendation and reasons
    Recommendation Do not list

  79. Dutasteride

    Brand name Avodart
    Manufacturer GlaxoSmithKline Inc.
    Indication Prostatic hyperplasia, benign
    Submission type Initial
    Project Number S0019
    Date submission received 2004-08-24
    Status Complete Submission status report
    Date recommendation issued 2005-01-20 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  80. Eculizumab

    Brand name Soliris
    Manufacturer Alexion Pharmaceuticals Inc.
    Indication Paroxysmal nocturnal hemoglobinuria (PNH)
    Submission type Initial
    Project Number S0176
    Date submission received 2009-09-18
    Status Complete Submission status report
    Date recommendation issued 2010-02-18 Recommendation and reasons
    Recommendation Do not list

  81. Efalizumab

    Brand name Raptiva
    Manufacturer Serono Canada Inc.
    Indication Psoriasis, moderate to severe chronic plaque
    Submission type Request for Advice
    Project Number S0102
    Date submission received 2007-06-19
    Status Complete Submission status report
    Recommendation

  82. Efalizumab

    Brand name Raptiva
    Manufacturer Serono Canada Inc.
    Indication Psoriasis, moderate to severe chronic plaque
    Submission type Initial
    Project Number S0043
    Date submission received 2005-10-25
    Status Complete Submission status report
    Date recommendation issued 2006-08-24 Recommendation and reasons
    Recommendation List with criteria/condition

  83. Efavirenz, emtricitabine, tenofovir disoproxil fumarate

    Brand name Atripla
    Manufacturer Bristol-Myers Squibb and Gilead Sciences
    Indication HIV
    Submission type Initial
    Project Number S0111
    Date submission received 2007-10-30
    Status Complete Submission status report
    Date recommendation issued 2008-04-17 Recommendation and reasons
    Recommendation List with criteria/condition

  84. Eletriptan hydrobromide

    Brand name Relpax
    Manufacturer Pfizer Canada Inc.
    Indication Migraine
    Submission type Initial
    Project Number S0021
    Date submission received 2004-09-21
    Status Complete Submission status report
    Date recommendation issued 2005-03-23 Recommendation and reasons
    Recommendation Do not list

  85. Eltrombopag olamine

    Brand name Revolade
    Manufacturer GlaxoSmithKline
    Indication Chronic immune (idiopathic) thrombocytopenic purpura
    Submission type Initial
    Project Number S0230
    Date submission received 2011-04-26
    Patient input deadline 2011-05-17
    Status Complete Submission status report
    Date recommendation issued 2011-10-24 Recommendation and reasons
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

  86. Emtricitabine / rilpivirine / tenofovir DF

    Brand name COMPLERA
    Manufacturer Gilead Science Canada Ltd.
    Indication HIV-1 infection in antiretroviral treatment- naïve adults
    Submission type Initial
    Project Number S0256
    Date submission received 2011-10-11
    Patient input deadline 2011-11-09
    Status Active Submission status report
    Recommendation

  87. Emtricitabine / tenofovir disoproxil fumarate

    Brand name Truvada
    Manufacturer Gilead Sciences Canada Inc.
    Indication HIV infection
    Submission type Request for Advice
    Project Number S0138
    Date submission received 2008-07-07
    Status Complete Submission status report
    Date recommendation issued 2008-12-17 Recommendation and reasons
    Recommendation List with criteria/condition

  88. Emtricitabine / tenofovir disoproxil fumarate

    Updated recommendation issued 2008-12-17 Recommendation and reasons
    Brand name Truvada
    Manufacturer Gilead Sciences Canada Inc.
    Indication HIV infection
    Submission type Initial
    Project Number S0063
    Date submission received 2006-05-29
    Status Complete Submission status report
    Date recommendation issued 2006-10-25 Recommendation and reasons
    Recommendation List with criteria/condition

  89. Entecavir

    Brand name Baraclude
    Manufacturer Bristol-Myers Squibb Canada
    Indication Hepatitis B (chronic)
    Submission type Initial
    Project Number S0089
    Date submission received 2006-12-12
    Status Complete Submission status report
    Date recommendation issued 2007-11-28 Recommendation and reasons
    Recommendation List with criteria/condition

  90. Eplerenone

    Brand name Inspra
    Manufacturer Pfizer Canada Inc.
    Indication Post myocardial infarction
    Submission type Initial
    Project Number S0165
    Date submission received 2009-05-06
    Status Complete Submission status report
    Date recommendation issued 2009-11-25 Recommendation and reasons
    Recommendation Do not list

  91. Eprosartan mesylate / hydrochlorothiazide

    Brand name Teveten Plus
    Manufacturer Solvay Pharma Inc.
    Indication High blood pressure
    Submission type Initial
    Project Number S0016
    Date submission received 2004-07-08
    Status Complete Submission status report
    Date recommendation issued 2004-12-15 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  92. Erlotinib

    Brand name Tarceva
    Manufacturer Hoffmann-La Roche Limited
    Indication Lung cancer, non-small cell
    Submission type Initial
    Project Number S0037
    Date submission received 2005-07-19
    Status Complete Submission status report
    Date recommendation issued 2005-12-07 Recommendation and reasons
    Recommendation List with criteria/condition

  93. Escitalopram oxalate

    Brand name Cipralex
    Manufacturer Lundbeck Canada Inc.
    Indication Depression, Major Depressive Disorder (MDD)
    Submission type Resubmission #1
    Project Number S0064
    Date submission received 2006-06-08
    Status Complete Submission status report
    Date recommendation issued 2007-01-24 Recommendation and reasons
    Recommendation Do not list

  94. Escitalopram oxalate

    Brand name Cipralex
    Manufacturer Lundbeck Canada Inc.
    Indication Depression, Major Depressive Disorder (MDD)
    Submission type Initial
    Project Number S0039
    Date submission received 2005-08-03
    Status Withdrawn Submission status report
    Recommendation

  95. Etonogestrel / ethinyl estradiol

    Brand name NuvaRing
    Manufacturer Organon Canada Ltd.
    Indication Contraceptive, ring
    Submission type Initial
    Project Number S0062
    Date submission received 2006-05-05
    Status Complete Submission status report
    Date recommendation issued 2006-11-29 Recommendation and reasons
    Recommendation List with criteria/condition

  96. Etravirine

    Brand name Intelence
    Manufacturer Janssen-Ortho Inc.
    Indication HIV
    Submission type Initial
    Project Number S0129
    Date submission received 2008-04-02
    Status Complete Submission status report
    Date recommendation issued 2008-08-14 Recommendation and reasons
    Recommendation List with criteria/condition

  97. Exenatide

    Brand name Byetta
    Manufacturer Eli Lilly Canada
    Indication Type 2 diabetes mellitus (T2DM)
    Submission type Initial
    Project Number S0246
    Date submission received 2011-08-09
    Patient input deadline 2011-09-14
    Status Active Submission status report
    Recommendation

  98. Febuxostat

    Brand name Uloric
    Manufacturer Takeda Canada Inc.
    Indication Gout
    Submission type Initial
    Project Number S0213
    Date submission received 2010-09-30
    Patient input deadline 2010-11-17
    Status Complete Submission status report
    Date recommendation issued 2011-04-25 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

  99. Fentanyl Citrate

    Brand name Onsolis
    Manufacturer Meda Valeant Pharma Canada Inc.
    Indication Pain (breakthrough), cancer (adults)
    Submission type Resubmission #1
    Project Number S0248
    Date submission received 2011-08-22
    Status Active Submission status report
    Recommendation

  100. Fentanyl citrate

    Brand name Abstral
    Manufacturer Paladin Labs Inc.
    Indication Management of breakthrough cancer pain
    Submission type Initial
    Project Number S0240
    Date submission received 2011-06-21
    Patient input deadline 2011-07-25
    Status Complete Submission status report
    Date recommendation issued 2011-12-16 Recommendation and reasons
    Recommendation Do not list

  101. Fentanyl Citrate

    Brand name Onsolis
    Manufacturer Meda Valeant Pharma Canada Inc.
    Indication Pain (breakthrough), cancer (adults)
    Submission type Initial
    Project Number S0229
    Date submission received 2011-03-04
    Patient input deadline 2011-06-01
    Status Withdrawn Submission status report
    Recommendation

  102. Fingolimod

    Brand name Gilenya
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Multiple Sclerosis
    Submission type Initial
    Project Number S0228
    Date submission received 2011-03-11
    Patient input deadline 2011-05-09
    Status Complete Submission status report
    Date recommendation issued 2011-11-16 Recommendation and reasons
    Recommendation List with criteria/condition

  103. Fosamprenavir calcium

    Brand name Telzir
    Manufacturer GlaxoSmithKline Inc.
    Indication HIV infection
    Submission type Initial
    Project Number S0030
    Date submission received 2005-01-24
    Status Complete Submission status report
    Date recommendation issued 2005-06-16 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  104. Gefitinib

    Brand name Iressa
    Manufacturer AstraZeneca
    Indication Lung cancer, non-small cell
    Submission type Initial
    Project Number S0003
    Date submission received 2003-12-22
    Status Complete Submission status report
    Date recommendation issued 2004-06-23 Recommendation and reasons
    Recommendation Do not list

  105. Glatiramer acetate

    Brand name Copaxone
    Manufacturer Teva Pharmaceutical Industries Ltd.
    Indication Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis
    Submission type New Indication
    Project Number S0164
    Date submission received 2009-04-29
    Status Complete Submission status report
    Date recommendation issued 2009-11-25 Recommendation and reasons
    Recommendation Do not list

  106. Golimumab

    Brand name Simponi
    Manufacturer Centocor Inc.
    Indication Arthritis, psoriatic
    Submission type Initial
    Project Number S0195
    Date submission received 2009-09-03
    Status Complete Submission status report
    Date recommendation issued 2010-03-17 Recommendation and reasons
    Recommendation List in a similar manner

  107. Golimumab

    Brand name Simponi
    Manufacturer Centocor Inc.
    Indication Arthritis, rheumatoid
    Submission type Initial
    Project Number S0174
    Date submission received 2009-09-03
    Status Complete Submission status report
    Date recommendation issued 2010-03-17 Recommendation and reasons
    Recommendation List in a similar manner

  108. Golimumab

    Brand name Simponi
    Manufacturer Centocor Inc.
    Indication Ankylosing spondylitis
    Submission type Initial
    Project Number S0196
    Date submission received 2009-09-03
    Status Complete Submission status report
    Date recommendation issued 2010-03-17 Recommendation and reasons
    Recommendation List in a similar manner

  109. Histrelin acetate

    Brand name Vantas
    Manufacturer Paladin Labs Inc.
    Indication Prostate Cancer
    Submission type Initial
    Project Number S0078
    Date submission received 2006-09-20
    Status Complete Submission status report
    Date recommendation issued 2007-04-26 Recommendation and reasons
    Recommendation Do not list

  110. Hydromorphone hydrochloride

    Brand name Jurnista
    Manufacturer Janssen-Ortho Inc.
    Indication Chronic Pain (moderate to severe)
    Submission type Initial
    Project Number S0190
    Date submission received 2009-12-04
    Status Complete Submission status report
    Date recommendation issued 2010-05-19 Recommendation and reasons
    Recommendation Do not list

  111. Idursulfase

    Brand name Elaprase
    Manufacturer Shire Human Genetic Therapies, Inc.
    Indication Mucopolysarccharidosis II (MPS II), Hunter Syndrome
    Submission type Initial
    Project Number S0104
    Date submission received 2007-07-13
    Status Complete Submission status report
    Date recommendation issued 2007-12-19 Recommendation and reasons
    Recommendation Do not list

  112. Infliximab

    Brand name Remicade
    Manufacturer Centocor Inc.
    Indication Ulcerative Colitis
    Submission type Initial
    Project Number S0146
    Date submission received 2008-09-29
    Status Complete Submission status report
    Date recommendation issued 2009-04-22 Recommendation and reasons
    Recommendation Do not list

  113. Insulin aspart / insulin aspart protamine

    Brand name NovoMix 30
    Manufacturer Novo Nordisk Canada Inc.
    Indication Diabetes mellitus
    Submission type Initial
    Project Number S0041
    Date submission received 2005-10-13
    Status Complete Submission status report
    Date recommendation issued 2006-04-26 Recommendation and reasons
    Recommendation Do not list

  114. Insulin detemir

    Brand name Levemir
    Manufacturer Novo Nordisk Canada Inc.
    Indication Diabetes mellitus
    Submission type Resubmission #2
    Project Number S0160
    Date submission received 2009-03-10
    Status Complete Submission status report
    Date recommendation issued 2009-08-19 Recommendation and reasons
    Recommendation Do not list

  115. Insulin detemir

    Brand name Levemir
    Manufacturer Novo Nordisk Canada Inc.
    Indication Diabetes Mellitus Type1, Pediatrics
    Submission type New Indication
    Project Number S0172
    Date submission received 2009-03-10
    Status Complete Submission status report
    Date recommendation issued 2009-08-19 Recommendation and reasons
    Recommendation Do not list

  116. Insulin detemir

    Brand name Levemir
    Manufacturer Novo Nordisk Canada Inc.
    Indication Diabetes mellitus
    Submission type Resubmission #1
    Project Number S0158
    Date submission received 2009-02-02
    Status Withdrawn Submission status report
    Recommendation

  117. Insulin detemir

    Brand name Levemir
    Manufacturer Novo Nordisk Canada Inc.
    Indication Diabetes mellitus
    Submission type Initial
    Project Number S0049
    Date submission received 2005-12-19
    Status Complete Submission status report
    Date recommendation issued 2006-08-02 Recommendation and reasons
    Recommendation Do not list

  118. Insulin glargine (rDNA origin)

    Brand name Lantus
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication Diabetes, Type 1 & 2
    Submission type Request for Advice
    Project Number S0166
    Date submission received 2009-06-09
    Status Complete Submission status report
    Recommendation

  119. Insulin glargine (rDNA origin)

    Brand name Lantus
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication Diabetes, Type 1 & 2
    Submission type Resubmission #1
    Project Number S0058
    Date submission received 2006-03-27
    Status Complete Submission status report
    Date recommendation issued 2006-10-25 Recommendation and reasons
    Recommendation Do not list

  120. Insulin glargine (rDNA origin)

    Brand name Lantus
    Manufacturer Aventis Pharma Inc.
    Indication Diabetes, Type 1 & 2
    Submission type Initial
    Project Number S0033
    Date submission received 2005-02-11
    Status Complete Submission status report
    Date recommendation issued 2005-09-28 Recommendation and reasons
    Recommendation Do not list

  121. Insulin glulisine

    Brand name Apidra
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication Diabetes (Type 1 & 2)
    Submission type Initial
    Project Number S0144
    Date submission received 2008-08-29
    Status Complete Submission status report
    Date recommendation issued 2009-02-19 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  122. Lacosamide

    Brand name Vimpat
    Manufacturer UCB Canada Inc.
    Indication Epilepsy, partial onset seizures (POS)
    Submission type Initial
    Project Number S0212
    Date submission received 2010-10-25
    Patient input deadline 2010-11-15
    Status Complete Submission status report
    Date recommendation issued 2011-04-25 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

  123. Lanreotide acetate

    Brand name Somatuline Autogel
    Manufacturer Ipsen Limited
    Indication Acromegaly
    Submission type Initial
    Project Number S0091
    Date submission received 2007-02-20
    Status Complete Submission status report
    Date recommendation issued 2007-07-19 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  124. Lanthanum carbonate hydrate

    Brand name Fosrenol
    Manufacturer Shire BioChem Inc.
    Indication Hyperphosphatemia, end-stage renal disease
    Submission type Initial
    Project Number S0100
    Date submission received 2007-06-28
    Status Complete Submission status report
    Date recommendation issued 2008-01-30 Recommendation and reasons
    Recommendation Do not list

  125. Laronidase

    Brand name Aldurazyme
    Manufacturer Genzyme Canada
    Indication Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie
    Submission type Initial
    Project Number S0032
    Date submission received 2005-02-03
    Status Complete Submission status report
    Date recommendation issued 2005-07-14 Recommendation and reasons
    Recommendation Do not list

  126. Levodopa / carbidopa

    Brand name Duodopa
    Manufacturer Solvay Pharma Inc.
    Indication Parkinson's disease
    Submission type Initial
    Project Number S0154
    Date submission received 2008-12-19
    Status Complete Submission status report
    Date recommendation issued 2009-07-22 Recommendation and reasons
    Recommendation Do not list

  127. Linagliptin

    Brand name Trajenta
    Manufacturer Boehringer Ingelheim Canada
    Indication Type 2 diabetes mellitus (T2DM)
    Submission type Initial
    Project Number S0244
    Date submission received 2011-08-09
    Patient input deadline 2011-09-14
    Status Active Submission status report
    Recommendation

  128. Liraglutide

    Brand name Victoza
    Manufacturer Novo Nordisk Canada Inc.
    Indication Diabetes, Type 2
    Submission type Initial
    Project Number S0217
    Date submission received 2010-10-12
    Patient input deadline 2011-01-10
    Status Complete Submission status report
    Date recommendation issued 2011-09-28 Recommendation and reasons
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

  129. Lisdexamfetamine dimesylate

    Brand name Vyvanse
    Manufacturer Shire Canada Inc.
    Indication Attention deficit hyperactivity disorder
    Submission type Initial
    Project Number S0171
    Date submission received 2009-07-10
    Status Complete Submission status report
    Date recommendation issued 2009-12-18 Recommendation and reasons
    Recommendation Do not list

  130. Loteprednol etabonate

    Brand name Lotemax
    Manufacturer Bausch & Lomb
    Indication Post-operative inflammation following cataract surgery
    Submission type Initial
    Project Number S0186
    Date submission received 2009-12-02
    Status Complete Submission status report
    Date recommendation issued 2010-05-19 Recommendation and reasons
    Recommendation Do not list

  131. Lumiracoxib

    Brand name Prexige
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Osteoarthritis (Knee)
    Submission type Initial
    Project Number S0090
    Date submission received 2006-12-15
    Status Complete Submission status report
    Date recommendation issued 2007-07-25 Recommendation and reasons
    Recommendation Do not list

  132. Maraviroc

    Brand name Celsentri
    Manufacturer GlaxoSmithKline
    Indication HIV-1, treatment naïve (adult)
    Submission type New Indication
    Project Number S0221
    Date submission received 2010-12-09
    Patient input deadline 2011-01-31
    Status Complete Submission status report
    Date recommendation issued 2011-07-18 Recommendation and reasons
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

  133. Maraviroc

    Brand name Celsentri
    Manufacturer Pfizer Canada Inc.
    Indication HIV
    Submission type Resubmission #1
    Project Number S0136
    Date submission received 2008-05-07
    Status Complete Submission status report
    Date recommendation issued 2008-11-12 Recommendation and reasons
    Recommendation List with criteria/condition

  134. Maraviroc

    Brand name Celsentri
    Manufacturer Pfizer Canada Inc.
    Indication HIV
    Submission type Initial
    Project Number S0113
    Date submission received 2007-11-02
    Status Withdrawn Submission status report
    Recommendation

  135. Memantine hydrochloride

    Brand name Ebixa
    Manufacturer Lundbeck Canada Inc.
    Indication Dementia of the Alzheimer type, moderate to severe
    Submission type Initial
    Project Number S0025
    Date submission received 2004-12-21
    Status Complete Submission status report
    Date recommendation issued 2005-11-23 Recommendation and reasons
    Recommendation Do not list

  136. Methylnaltrexone bromide

    Brand name Relistor
    Manufacturer Wyeth Canada
    Indication Constipation, Opioid-induced
    Submission type Initial
    Project Number S0135
    Date submission received 2008-05-07
    Status Complete Submission status report
    Date recommendation issued 2009-01-28 Recommendation and reasons
    Recommendation Do not list

  137. Miglustat

    Brand name Zavesca
    Manufacturer Actelion Pharmaceuticals Canada Inc.
    Indication Gaucher disease
    Submission type Initial
    Project Number S0012
    Date submission received 2004-05-13
    Status Complete Submission status report
    Date recommendation issued 2004-11-24 Recommendation and reasons
    Recommendation Do not list

  138. Mixed amphetamine salts

    Brand name Adderall XR
    Manufacturer Shire Canada Inc.
    Indication Attention deficit hyperactivity disorder, Adult
    Submission type New Indication
    Project Number S0116
    Date submission received 2007-11-29
    Status Complete Submission status report
    Date recommendation issued 2008-06-25 Recommendation and reasons
    Recommendation Do not list
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

  139. Mixed amphetamine salts

    Brand name Adderall XR
    Manufacturer Shire BioChem Inc.
    Indication Attention deficit hyperactivity disorder
    Submission type Resubmission #1
    Project Number S0027
    Date submission received 2004-12-15
    Status Withdrawn Submission status report
    Recommendation

  140. Mixed amphetamine salts

    Brand name Adderall XR
    Manufacturer Shire BioChem Inc.
    Indication Attention deficit hyperactivity disorder
    Submission type Initial
    Project Number S0010
    Date submission received 2004-04-13
    Status Complete Submission status report
    Date recommendation issued 2004-11-24 Recommendation and reasons
    Recommendation Do not list

  141. Mometasone furoate

    Brand name ASMANEX
    Manufacturer Merck Canada Inc.
    Indication Prophylactic management of steroid-response bronchial asthma
    Submission type Initial
    Project Number SR0258
    Date submission received 2011-11-17
    Patient input deadline 2011-11-21
    Status Active Submission status report
    Recommendation

  142. Mometasone furoate & formoterol

    Brand name Zenhale (inhalation aerosol)
    Manufacturer Merck Canada
    Indication Asthma maintenance (adults, children 12 or older)
    Submission type Initial
    Project Number S0225
    Date submission received 2011-01-31
    Patient input deadline 2011-03-10
    Status Complete Submission status report
    Date recommendation issued 2011-09-28 Recommendation and reasons
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

  143. Mycophenolate sodium

    Brand name Myfortic
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Prophylaxis of organ rejection in allogeneic renal transplants
    Submission type Initial
    Project Number S0034
    Date submission received 2005-03-03
    Status Complete Submission status report
    Date recommendation issued 2005-07-08 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  144. Natalizumab

    Brand name Tysabri
    Manufacturer Biogen Idec Canada Inc.
    Indication Multiple Sclerosis, relapsing-remitting
    Submission type Resubmission #1
    Project Number S0133
    Date submission received 2008-05-06
    Status Complete Submission status report
    Date recommendation issued 2009-02-25 Recommendation and reasons
    Recommendation List with criteria/condition

  145. Natalizumab

    Brand name Tysabri
    Manufacturer Biogen Idec Canada Inc.
    Indication Multiple Sclerosis, relapsing-remitting
    Submission type Initial
    Project Number S0082
    Date submission received 2006-10-26
    Status Complete Submission status report
    Date recommendation issued 2007-04-26 Recommendation and reasons
    Recommendation Do not list

  146. Niacin / lovastatin

    Brand name Advicor
    Manufacturer Oryx Pharmaceuticals Inc.
    Indication Hypercholesterolemia and mixed dyslipidemia
    Submission type Initial
    Project Number S0042
    Date submission received 2005-10-18
    Status Complete Submission status report
    Date recommendation issued 2006-04-26 Recommendation and reasons
    Recommendation List

  147. Norgelestromin / ethinyl estradiol

    Brand name Evra
    Manufacturer Janssen-Ortho Inc.
    Indication Contraceptive, patch
    Submission type Initial
    Project Number S0004
    Date submission received 2003-12-19
    Status Complete Submission status report
    Date recommendation issued 2004-06-23 Recommendation and reasons
    Recommendation Do not list

  148. Olmesartan medoxomil

    Brand name Olmetec
    Manufacturer Schering-Plough Canada Inc.
    Indication Hypertension
    Submission type Initial
    Project Number S0150
    Date submission received 2008-11-28
    Status Complete Submission status report
    Date recommendation issued 2009-05-27 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  149. Olmesartan medoxomil + hydrochlorothiazide

    Brand name Olmetec Plus
    Manufacturer Schering-Plough Canada Inc.
    Indication Hypertension
    Submission type Initial
    Project Number S0151
    Date submission received 2008-11-28
    Status Complete Submission status report
    Date recommendation issued 2009-05-27 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  150. Omalizumab

    Brand name Xolair
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Asthma, severe persistent
    Submission type Resubmission #1
    Project Number S0045
    Date submission received 2005-10-13
    Status Complete Submission status report
    Date recommendation issued 2006-03-07 Recommendation and reasons
    Recommendation Do not list

  151. Omalizumab

    Brand name Xolair
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Asthma, severe persistent
    Submission type Initial
    Project Number S0035
    Date submission received 2005-04-18
    Status Suspended Submission status report
    Recommendation

  152. OnabotulinumtoxinA

    Brand name Botox
    Manufacturer Allergan Inc.
    Indication Neurogenic Detrusor Overactivity
    Submission type Initial
    Project Number SR0268
    Date submission received 2012-01-23
    Patient input deadline 2012-02-17 Patient Input
    Status Pending Submission status report
    Recommendation

  153. Oxybutynin Chloride Gel

    Brand name GELNIQUE
    Manufacturer Watson Pharma Company
    Indication Treatment of overactive bladder (OAB)
    Submission type Initial
    Project Number S0260
    Date submission received 2011-10-13
    Patient input deadline 2011-11-17
    Status Active Submission status report
    Recommendation

  154. Oxycodone HCI / naloxone HCI

    Brand name Targin
    Manufacturer Purdue Pharma
    Indication Moderate to severe pain and relief of opioid-induced constipation
    Submission type Resubmission #1
    Project Number S0241
    Date submission received 2011-07-05
    Status Active Submission status report
    Date recommendation issued 2012-01-25 Recommendation and reasons
    Recommendation Do not list

  155. Oxycodone HCI / naloxone HCI

    Brand name Targin
    Manufacturer Purdue Pharma
    Indication Moderate to severe pain and relief of opioid-induced constipation
    Submission type Initial
    Project Number S0219
    Date submission received 2010-12-02
    Patient input deadline 2011-01-21
    Status Stopped Submission status report
    Recommendation

  156. Paliperidone

    Brand name Invega
    Manufacturer Janssen-Ortho Inc.
    Indication Schizophrenia
    Submission type Initial
    Project Number S0112
    Date submission received 2007-11-01
    Status Complete Submission status report
    Date recommendation issued 2008-05-28 Recommendation and reasons
    Recommendation Do not list

  157. Paliperidone palmitate

    Brand name Invega Sustenna
    Manufacturer Janssen-Ortho Inc.
    Indication Schizophrenia
    Submission type Initial
    Project Number S0206
    Date submission received 2010-06-22
    Patient input deadline 2010-07-30
    Status Complete Submission status report
    Date recommendation issued 2011-04-25 Recommendation and reasons
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

  158. Pantoprazole magnesium

    Brand name Pantoloc M
    Manufacturer Altana Pharma Inc.
    Indication Gastric acid secretion, reduction of
    Submission type Initial
    Project Number S0054
    Date submission received 2006-03-17
    Status Complete Submission status report
    Date recommendation issued 2006-07-20 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  159. Pegaptanib sodium

    Brand name Macugen
    Manufacturer Pfizer Canada Inc.
    Indication Macular degeneration, age-related
    Submission type Initial
    Project Number S0044
    Date submission received 2005-10-20
    Status Complete Submission status report
    Date recommendation issued 2006-05-25 Recommendation and reasons
    Recommendation Do not list

  160. Pegfilgrastim

    Brand name Neulasta
    Manufacturer Amgen Canada Inc.
    Indication Neutropenia
    Submission type Initial
    Project Number S0009
    Date submission received 2004-03-29
    Status Complete Submission status report
    Date recommendation issued 2004-10-27 Recommendation and reasons
    Recommendation List with criteria/condition

  161. Peginterferon alfa-2a and Ribavirin

    Brand name Pegasys RBV
    Manufacturer Hoffman-La Roche Ltd.
    Indication Hepatitis C, chronic
    Submission type Initial
    Project Number S0013
    Date submission received 2004-05-14
    Status Complete Submission status report
    Date recommendation issued 2004-10-14 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  162. Pegvisomant

    Brand name Somavert
    Manufacturer Pfizer Canada Inc.
    Indication acromegaly
    Submission type Initial
    Project Number S0050
    Date submission received 2006-01-25
    Status Complete Submission status report
    Date recommendation issued 2006-08-02 Recommendation and reasons
    Recommendation Do not list

  163. Penciclovir

    Brand name Denavir
    Manufacturer Novartis Consumer Health Care Inc.
    Indication Herpes labialis (cold sores)
    Submission type Initial
    Project Number S0075
    Date submission received 2006-09-20
    Status Complete Submission status report
    Date recommendation issued 2007-04-26 Recommendation and reasons
    Recommendation Do not list

  164. Plerixafor

    Brand name Mozobil
    Manufacturer Genzyme Canada Inc.
    Indication Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma
    Submission type Initial
    Project Number SR0265
    Date submission received 2012-01-26
    Patient input deadline 2012-02-15 Patient Input
    Status Active Submission status report
    Recommendation

  165. Posaconazole

    Brand name Spriafil
    Manufacturer Schering-Plough Canada Inc.
    Indication Aspergillus and Candida infections
    Submission type Initial
    Project Number S0097
    Date submission received 2007-05-24
    Status Complete Submission status report
    Date recommendation issued 2008-01-30 Recommendation and reasons
    Recommendation Do not list

  166. Prasugrel

    Brand name Effient
    Manufacturer Eli Lily Canada Inc.
    Indication Acute Coronary Syndrome (ACS)
    Submission type Resubmission #1
    Project Number S0263
    Date submission received 2011-12-16
    Patient input deadline 2012-01-16
    Status Active Submission status report
    Recommendation

  167. Prasugrel hydrochloride

    Brand name Effient
    Manufacturer Eli Lilly Canada Inc.
    Indication Acute Coronary Syndrome (ACS)
    Submission type Initial
    Project Number S0200
    Date submission received 2010-05-05
    Status Complete Submission status report
    Date recommendation issued 2011-02-16 Recommendation and reasons
    Recommendation Do not list

  168. Pregabalin

    Brand name Lyrica
    Manufacturer Pfizer Canada Inc.
    Indication diabetic peripheral neuropathy
    Submission type Resubmission #1
    Project Number S0162
    Date submission received 2009-03-20
    Status Complete Submission status report
    Date recommendation issued 2009-09-23 Recommendation and reasons
    Recommendation Do not list

  169. Pregabalin

    Brand name Lyrica
    Manufacturer Pfizer Canada Inc.
    Indication Neuropathic pain
    Submission type Initial
    Project Number S0036
    Date submission received 2005-06-27
    Status Complete Submission status report
    Date recommendation issued 2006-01-25 Recommendation and reasons
    Recommendation Do not list

  170. Prucalopride

    Brand name Resotran
    Manufacturer Janssen Inc.
    Indication Constipation, chronic
    Submission type Initial
    Project Number SR0266
    Date submission received 2012-01-17
    Patient input deadline 2012-02-22 Patient Input
    Status Pending Submission status report
    Recommendation

  171. Quinagolide hydrochloride

    Brand name Norprolac
    Manufacturer Ferring Pharmaceuticals
    Indication Hyperprolactinemia
    Submission type Resubmission #1
    Project Number S0046
    Date submission received 2005-11-23
    Status Complete Submission status report
    Date recommendation issued 2006-05-17 Recommendation and reasons
    Recommendation List with criteria/condition

  172. Quinagolide hydrochloride

    Brand name Norprolac
    Manufacturer Ferring Pharmaceuticals
    Indication Hyperprolactinemia
    Submission type Initial
    Project Number S0026
    Date submission received 2004-12-16
    Status Complete Submission status report
    Date recommendation issued 2005-09-28 Recommendation and reasons
    Recommendation Do not list

  173. Raltegravir

    Brand name Isentress
    Manufacturer Merck Frosst Canada Ltd.
    Indication HIV (treatment naïve)
    Submission type New Indication
    Project Number S0191
    Date submission received 2009-12-04
    Status Complete Submission status report
    Date recommendation issued 2010-06-23 Recommendation and reasons
    Recommendation Do not list

  174. Raltegravir

    Brand name Isentress
    Manufacturer Merck Frosst Canada Ltd.
    Indication HIV
    Submission type Initial
    Project Number S0115
    Date submission received 2007-11-29
    Status Complete Submission status report
    Date recommendation issued 2008-05-14 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

  175. Ramipril / felodipine extended release

    Brand name Altace Plus Felodipine
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication Hypertension
    Submission type Initial
    Project Number S0067
    Date submission received 2006-06-22
    Status Complete Submission status report
    Date recommendation issued 2006-11-15 Recommendation and reasons
    Recommendation Do not list

  176. Ramipril / hydrochlorothiazide

    Brand name Altace HCT
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication Hypertension
    Submission type Resubmission #1
    Project Number S0095
    Date submission received 2007-03-26
    Status Complete Submission status report
    Date recommendation issued 2007-06-14 Recommendation and reasons
    Recommendation List

  177. Ramipril / hydrochlorothiazide

    Brand name Altace HCT
    Manufacturer Sanofi –Aventis Canada inc.
    Indication Hypertension
    Submission type Initial
    Project Number S0083
    Date submission received 2006-10-26
    Status Suspended Submission status report
    Recommendation

  178. Ranibizumab

    Brand name Lucentis
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Visual impairment due to diabetic macular edema
    Submission type New Indication
    Project Number S0253
    Date submission received 2011-08-31
    Patient input deadline 2011-10-05
    Status Active Submission status report
    Recommendation

  179. Ranibizumab

    Brand name Lucentis
    Manufacturer Novartis Pharmaceuticals Inc.
    Indication Macular degeneration, age-related
    Submission type Initial
    Project Number S0098
    Date submission received 2007-07-12
    Status Complete Submission status report
    Date recommendation issued 2008-03-27 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

  180. Rasagiline mesylate

    Brand name Azilect
    Manufacturer Teva Pharmaceuticals Industries Ltd.
    Indication Parkinson’s disease
    Submission type Request for Advice
    Project Number S0161
    Date submission received 2009-03-10
    Status Complete Submission status report
    Recommendation

  181. Rasagiline mesylate

    Brand name Azilect
    Manufacturer Teva Neurosciences
    Indication Parkinson's disease
    Submission type Initial
    Project Number S0073
    Date submission received 2006-09-01
    Status Complete Submission status report
    Date recommendation issued 2007-03-28 Recommendation and reasons
    Recommendation Do not list

  182. Rilpivirine

    Brand name Edurant
    Manufacturer Janssen Inc.
    Indication HIV in treatment- naïve adult patients
    Submission type Initial
    Project Number S0243
    Date submission received 2011-07-15
    Patient input deadline 2011-08-22
    Status Active Submission status report
    Recommendation

  183. Rituximab

    Brand name Rituxan
    Manufacturer Hoffmann-La Roche Limited
    Indication Arthritis, rheumatoid
    Submission type Initial
    Project Number S0068
    Date submission received 2006-06-26
    Status Complete Submission status report
    Date recommendation issued 2007-02-14 Recommendation and reasons
    Recommendation List with criteria/condition

  184. Rivaroxaban

    Brand name Xarelto
    Manufacturer Bayer Inc.
    Indication Stroke Prevention in Patients with Atrial Fibrillation
    Submission type Pre-NOC
    Project Number S0257
    Date submission received 2011-10-18
    Patient input deadline 2011-11-09
    Status Active Submission status report
    Recommendation

  185. Rivaroxaban

    Brand name Xarelto
    Manufacturer Bayer Inc.
    Indication Venous thromboembolism prevention
    Submission type Request for Advice
    Project Number S0239
    Date submission received 2011-06-24
    Status Complete Submission status report
    Recommendation

  186. Rivaroxaban

    Brand name Xarelto
    Manufacturer Bayer Inc.
    Indication Venous thromboembolism prevention
    Submission type Initial
    Project Number S0134
    Date submission received 2008-05-07
    Status Complete Submission status report
    Date recommendation issued 2008-12-17 Recommendation and reasons
    Recommendation List with criteria/condition

  187. Rivastigmine

    Brand name Exelon Patch
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Dementia (Alzheimer's type)
    Submission type Initial
    Project Number S0123
    Date submission received 2007-12-21
    Status Complete Submission status report
    Date recommendation issued 2008-07-23 Recommendation and reasons
    Recommendation Do not list

  188. Roflumilast

    Brand name Daxas
    Manufacturer Nycomed Canada Inc
    Indication Chronic obstructive pulmonary disease (COPD)
    Submission type Initial
    Project Number S0218
    Date submission received 2010-11-18
    Patient input deadline 2011-01-24
    Status Complete Submission status report
    Date recommendation issued 2011-07-27 Recommendation and reasons
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

  189. Romiplostim

    Brand name Nplate
    Manufacturer Amgen Canada Inc.
    Indication Chronic immune (idiopathic) thrombocytopenic purpura (ITP)
    Submission type Initial
    Project Number S0179
    Date submission received 2009-09-29
    Status Complete Submission status report
    Date recommendation issued 2010-05-27 Recommendation and reasons
    Recommendation Do not list

  190. Rufinamide

    Brand name Banzel
    Manufacturer Eisai Limited
    Indication Lennox-Gastaut Syndrome; Adjunctive treatment of seizures
    Submission type Initial
    Project Number S0252
    Date submission received 2011-09-07
    Patient input deadline 2011-10-13
    Status Active Submission status report
    Recommendation

  191. Sapropterin dihydrochloride

    Brand name Kuvan
    Manufacturer BioMarin Pharmaceutical Canada Inc.
    Indication Phenylketonuria (PKU).
    Submission type Request for Advice
    Project Number S0236
    Date submission received 2011-06-01
    Status Active Submission status report
    Recommendation

  192. Sapropterin dihydrochloride

    Brand name Kuvan
    Manufacturer BioMarin Pharmaceutical Canada Inc.
    Indication Phenylketonuria (PKU).
    Submission type Initial
    Project Number S0205
    Date submission received 2010-07-05
    Patient input deadline 2010-07-29
    Status Complete Submission status report
    Date recommendation issued 2011-01-26 Recommendation and reasons
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

  193. Saxagliptin

    Brand name Onglyza
    Manufacturer Bristol-Myers Squibb Canada
    Indication Diabetes Mellitus (Type 2)
    Submission type Initial
    Project Number S0185
    Date submission received 2009-11-09
    Status Complete Submission status report
    Date recommendation issued 2010-06-17 Recommendation and reasons
    Recommendation Do not list

  194. Sildenafil citrate

    Brand name Revatio
    Manufacturer Pfizer Canada Inc.
    Indication Pulmonary arterial hypertension (WHO class II and III)
    Submission type Initial
    Project Number S0076
    Date submission received 2006-09-20
    Status Complete Submission status report
    Date recommendation issued 2007-02-14 Recommendation and reasons
    Recommendation List in a similar manner

  195. Silodosin

    Brand name RAPAFLO
    Manufacturer Watson Pharma Company
    Indication Treatment of benign prostatic hyperplasia (BPH)
    Submission type Initial
    Project Number S0261
    Date submission received 2011-10-13
    Patient input deadline 2011-11-17
    Status Active Submission status report
    Recommendation

  196. Sitagliptin phosphate

    Brand name Januvia
    Manufacturer Merck Frosst Canada Ltd.
    Indication Diabetes Mellitus (Type 2)
    Submission type Resubmission #1
    Project Number S0181
    Date submission received 2009-10-29
    Status Complete Submission status report
    Date recommendation issued 2010-06-23 Recommendation and reasons
    Recommendation List with criteria/condition

  197. Sitagliptin phosphate

    Brand name Januvia
    Manufacturer Merck Frosst Canada Ltd.
    Indication Diabetes Mellitus (Type 2)
    Submission type Initial
    Project Number S0122
    Date submission received 2007-12-20
    Status Complete Submission status report
    Date recommendation issued 2008-06-18 Recommendation and reasons
    Recommendation Do not list
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

  198. Sitagliptin phosphate monohydrate / metformin hydrochloride

    Brand name Janumet
    Manufacturer Merck Frosst Canada Ltd.
    Indication Diabetes Mellitus (Type 2)
    Submission type Initial
    Project Number S0182
    Date submission received 2009-11-04
    Status Complete Submission status report
    Date recommendation issued 2010-06-23 Recommendation and reasons
    Recommendation List with criteria/condition

  199. Sitaxsentan sodium

    Brand name Thelin
    Manufacturer Encysive Canada Inc.
    Indication Pulmonary arterial hypertension (WHO class II and III)
    Submission type Resubmission #1
    Project Number S0132
    Date submission received 2008-05-05
    Status Complete Submission status report
    Date recommendation issued 2009-01-28 Recommendation and reasons
    Recommendation Do not list

  200. Sitaxsentan sodium

    Brand name Thelin
    Manufacturer Encysive Canada Inc.
    Indication Pulmonary arterial hypertension (WHO class II and III)
    Submission type Initial
    Project Number S0099
    Date submission received 2007-06-22
    Status Complete Submission status report
    Date recommendation issued 2008-01-30 Recommendation and reasons
    Recommendation Do not list

  201. Sodium oxybate

    Brand name Xyrem
    Manufacturer Valeant Canada Ltd.
    Indication Narcolepsy
    Submission type Resubmission #1
    Project Number S0141
    Date submission received 2008-07-09
    Status Complete Submission status report
    Date recommendation issued 2009-01-28 Recommendation and reasons
    Recommendation Do not list

  202. Sodium oxybate

    Brand name Xyrem
    Manufacturer Valeant Canada Ltd.
    Indication Narcolepsy
    Submission type Initial
    Project Number S0107
    Date submission received 2007-08-29
    Status Withdrawn Submission status report
    Recommendation

  203. Solifenacin succinate

    Brand name Vesicare
    Manufacturer Astellas Pharma Canada Inc.
    Indication Bladder, overactive
    Submission type Resubmission #1
    Project Number S0155
    Date submission received 2009-01-05
    Status Complete Submission status report
    Date recommendation issued 2009-06-17 Recommendation and reasons
    Recommendation List with criteria/condition

  204. Solifenacin succinate

    Brand name Vesicare
    Manufacturer Astellas Pharma Canada Inc.
    Indication Bladder, overactive
    Submission type Initial
    Project Number S0070
    Date submission received 2006-07-24
    Status Complete Submission status report
    Date recommendation issued 2007-01-24 Recommendation and reasons
    Recommendation Do not list

  205. Somatropin (rDNA origin)

    Brand name Omnitrope
    Manufacturer Sandoz Canada Inc.
    Indication Growth hormone deficiency in children and adults
    Submission type Initial
    Project Number S0167
    Date submission received 2009-06-12
    Status Complete Submission status report
    Date advice issued 2009-12-16 Advice - SEB
    Recommendation

  206. Sorafenib tablets

    Brand name Nexavar
    Manufacturer Bayer Inc.
    Indication Renal cell carcinoma
    Submission type Initial
    Project Number S0071
    Date submission received 2006-07-31
    Status Complete Submission status report
    Date recommendation issued 2007-02-28 Recommendation and reasons
    Recommendation Do not list

  207. Sunitinib

    Brand name Sutent
    Manufacturer Pfizer Canada Inc.
    Indication Gastrointestinal stromal tumour (GIST)
    Submission type Initial
    Project Number S0069
    Date submission received 2006-07-20
    Status Complete Submission status report
    Date recommendation issued 2007-03-28 Recommendation and reasons
    Recommendation List with criteria/condition

  208. Sunitinib malate

    Brand name Sutent
    Manufacturer Pfizer Canada Inc.
    Indication Metastatic renal cell carcinoma
    Submission type Resubmission #1
    Project Number S0077
    Date submission received 2006-09-20
    Status Complete Submission status report
    Date recommendation issued 2007-04-26 Recommendation and reasons
    Recommendation Do not list

  209. Tadalafil

    Brand name Adcirca
    Manufacturer Eli Lilly Canada Inc.
    Indication Pulmonary Arterial Hypertension
    Submission type Initial
    Project Number S0197
    Date submission received 2010-02-05
    Status Complete Submission status report
    Date recommendation issued 2010-07-15 Recommendation and reasons
    Recommendation List with criteria/condition

  210. Tapentadol

    Brand name Nucynta CR
    Manufacturer Janssen Inc.
    Indication Pain, moderate to moderately severe
    Submission type Initial
    Project Number S0224
    Date submission received 2011-01-20
    Patient input deadline 2011-02-24
    Status Complete Submission status report
    Date recommendation issued 2011-09-28 Recommendation and reasons
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

  211. Telaprevir

    Brand name Incivek
    Manufacturer Vertex Pharmaceuticals Inc.
    Indication Chronic hepatitis C infection (genotype 1)
    Submission type Initial
    Project Number S0249
    Date submission received 2011-08-16
    Patient input deadline 2011-09-14
    Status Active Submission status report
    Recommendation

  212. Telbivudine

    Brand name Sebivo
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Hepatitis B (chronic)
    Submission type Initial
    Project Number S0088
    Date submission received 2006-12-04
    Status Complete Submission status report
    Date recommendation issued 2007-09-26 Recommendation and reasons
    Recommendation Do not list

  213. Telmisartan / Amlodipine

    Brand name Twynsta
    Manufacturer Boehringer Ingelheim (Canada) Ltd
    Indication Essential Hypertension
    Submission type Pre-NOC
    Project Number S0207
    Date submission received 2010-07-09
    Patient input deadline 2010-07-30
    Status Rejected Submission status report
    Recommendation

  214. Telmisartan / Amlodipine

    Brand name Twynsta
    Manufacturer Boehringer Ingelheim Canada
    Indication Essential Hypertension
    Submission type Initial
    Project Number S0245
    Date submission received 2011-08-09
    Patient input deadline 2011-09-14
    Status Complete Submission status report
    Date recommendation issued 2011-12-16 Recommendation and reasons
    Recommendation List

  215. Tenofovir disoproxil fumarate

    Brand name Viread
    Manufacturer Gilead Sciences Canada Inc.
    Indication Hepatitis B (Chronic)
    Submission type New Indication
    Project Number S0148
    Date submission received 2008-10-02
    Status Complete Submission status report
    Date recommendation issued 2009-03-18 Recommendation and reasons
    Recommendation List with criteria/condition

  216. Tenofovir disoproxil fumarate

    Brand name Viread
    Manufacturer Gilead Sciences Canada Inc.
    Indication HIV infection
    Submission type Request for Advice
    Project Number S0139
    Date submission received 2008-07-07
    Status Complete Submission status report
    Recommendation

  217. Tenofovir disoproxil fumarate

    Brand name Viread
    Manufacturer Gilead Sciences Canada Inc.
    Indication HIV infection
    Submission type Resubmission #1
    Project Number S0040
    Date submission received 2005-08-11
    Status Complete Submission status report
    Date recommendation issued 2006-03-15 Recommendation and reasons
    Recommendation List with criteria/condition

  218. Tenofovir disoproxil fumarate

    Brand name Viread
    Manufacturer Gilead Sciences Canada Inc.
    Indication HIV infection
    Submission type Initial
    Project Number S0008
    Date submission received 2004-02-23
    Status Complete Submission status report
    Date recommendation issued 2004-08-25 Recommendation and reasons
    Recommendation Do not list

  219. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication Severe osteoporosis in women
    Submission type ACP Submission
    Project Number S0180
    Date submission received 2009-10-23
    Status Complete Submission status report
    Date recommendation issued 2010-03-17 Recommendation and reasons
    Recommendation Do not list

  220. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication Osteoporosis
    Submission type Resubmission #3
    Project Number S0169
    Date submission received 2009-06-12
    Status Withdrawn Submission status report
    Recommendation

  221. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication Osteoporosis
    Submission type Resubmission #2
    Project Number S0157
    Date submission received 2008-12-18
    Status Withdrawn Submission status report
    Recommendation

  222. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication Osteoporosis (glucocorticoid induced)
    Submission type New Indication
    Project Number S0152
    Date submission received 2008-12-18
    Status Complete Submission status report
    Date recommendation issued 2009-07-22 Recommendation and reasons
    Recommendation Do not list

  223. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication Osteoporosis
    Submission type Resubmission #1
    Project Number S0065
    Date submission received 2006-05-29
    Status Withdrawn Submission status report
    Recommendation

  224. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication Osteoporosis
    Submission type Initial
    Project Number S0015
    Date submission received 2004-06-08
    Status Complete Submission status report
    Date recommendation issued 2004-12-22 Recommendation and reasons
    Recommendation Do not list

  225. Ticagrelor

    Brand name Brilinta
    Manufacturer AstraZeneca Canada Inc
    Indication Prevention of thrombotic events in Acute Coronary Syndromes
    Submission type Initial
    Project Number S0234
    Date submission received 2011-05-17
    Patient input deadline 2011-06-22
    Status Complete Submission status report
    Date recommendation issued 2011-12-16 Recommendation and reasons
    Recommendation Do not list

  226. Ticagrelor

    Brand name Brilinta
    Manufacturer AstraZeneca Canada Inc
    Indication Acute Coronary Syndromes (ACS)
    Submission type Pre-NOC - Initial
    Project Number S0203
    Date submission received 2010-06-08
    Patient input deadline 2010-06-30
    Status Stopped Submission status report
    Recommendation

  227. Tipranavir

    Brand name Aptivus
    Manufacturer Boehringer Ingelheim (Canada) Inc.
    Indication HIV infection
    Submission type Initial
    Project Number S0047
    Date submission received 2005-12-15
    Status Complete Submission status report
    Date recommendation issued 2006-05-17 Recommendation and reasons
    Recommendation List with criteria/condition

  228. Tocilizumab

    Brand name Actemra
    Manufacturer Hoffman-La Roche Ltd.
    Indication Arthritis, juvenile idiopathic
    Submission type New Indication
    Project Number S0267
    Date submission received 2012-01-30
    Patient input deadline 2012-02-17 Patient Input
    Status Active Submission status report
    Recommendation

  229. Tocilizumab

    Brand name Actemra
    Manufacturer Hoffmann-La Roche Limited
    Indication Arthritis, Rheumatoid
    Submission type Initial
    Project Number S0201
    Date submission received 2010-05-21
    Patient input deadline 2010-06-17
    Status Complete Submission status report
    Date recommendation issued 2010-11-17 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

  230. Tramadol hydrochloride

    Brand name Tridural
    Manufacturer Labopharm Inc.
    Indication Pain
    Submission type Initial
    Project Number S0117
    Date submission received 2007-11-29
    Status Complete Submission status report
    Date recommendation issued 2008-04-17 Recommendation and reasons
    Recommendation Do not list

  231. Tramadol hydrochloride

    Brand name Ralivia
    Manufacturer Biovail Pharmaceuticals Canada
    Indication Pain
    Submission type Initial
    Project Number S0110
    Date submission received 2007-10-29
    Status Complete Submission status report
    Date recommendation issued 2008-06-25 Recommendation and reasons
    Recommendation Do not list

  232. Tramadol hydrochloride

    Brand name Zytram XL
    Manufacturer Purdue Pharma
    Indication Pain
    Submission type Resubmission #1
    Project Number S0093
    Date submission received 2007-03-15
    Status Complete Submission status report
    Date recommendation issued 2007-09-26 Recommendation and reasons
    Recommendation Do not list

  233. Tramadol hydrochloride

    Brand name Zytram XL
    Manufacturer Purdue Pharma
    Indication Acute pain
    Submission type Initial
    Project Number S0086
    Date submission received 2006-11-03
    Status Withdrawn Submission status report
    Recommendation

  234. Tramadol hydrochloride / acetaminophen

    Brand name Tramacet
    Manufacturer Janssen-Ortho Inc.
    Indication Acute pain
    Submission type Initial
    Project Number S0079
    Date submission received 2006-10-02
    Status Complete Submission status report
    Date recommendation issued 2007-05-17 Recommendation and reasons
    Recommendation Do not list

  235. Travoprost and timolol maleate

    Brand name DuoTrav
    Manufacturer Alcon Canada Inc.
    Indication Glaucoma
    Submission type Initial
    Project Number S0057
    Date submission received 2006-03-24
    Status Complete Submission status report
    Date recommendation issued 2006-08-24 Recommendation and reasons
    Recommendation List with criteria/condition

  236. Treprostinil sodium

    Brand name Remodulin
    Manufacturer Northern Therapeutics Inc.
    Indication Pulmonary arterial hypertension (NYHA Class III and IV patients)
    Submission type Resubmission #1
    Project Number S0052
    Date submission received 2006-02-24
    Status Complete Submission status report
    Date recommendation issued 2006-07-20 Recommendation and reasons
    Recommendation List with criteria/condition

  237. Treprostinil sodium

    Brand name Remodulin
    Manufacturer Northern Therapeutics Inc.
    Indication Pulmonary arterial hypertension (NYHA Class III and IV patients)
    Submission type Initial
    Project Number S0011
    Date submission received 2004-07-14
    Status Complete Submission status report
    Date recommendation issued 2004-11-17 Recommendation and reasons
    Recommendation Do not list

  238. Triptorelin pamoate

    Brand name Trelstar
    Manufacturer Watson Laboratories Inc.
    Indication Prostate cancer
    Submission type Initial
    Project Number S0051
    Date submission received 2006-02-27
    Status Complete Submission status report
    Date recommendation issued 2006-07-20 Recommendation and reasons
    Recommendation List in a similar manner to other drugs in class

  239. Trospium chloride

    Brand name Trosec
    Manufacturer Oryx Pharmaceuticals Inc.
    Indication Bladder, overactive
    Submission type Initial
    Project Number S0055
    Date submission received 2006-03-24
    Status Complete Submission status report
    Date recommendation issued 2006-08-24 Recommendation and reasons
    Recommendation List with criteria/condition

  240. Ustekinumab

    Brand name Stelara
    Manufacturer Janssen-Ortho Inc.
    Indication Psoriasis
    Submission type Initial
    Project Number S0156
    Date submission received 2009-01-07
    Status Complete Submission status report
    Date recommendation issued 2009-06-17 Recommendation and reasons
    Recommendation List with criteria/condition

  241. Varenicline tartrate

    Brand name Champix
    Manufacturer Pfizer Canada Inc.
    Indication Smoking-cessation
    Submission type Initial
    Project Number S0094
    Date submission received 2007-03-21
    Status Complete Submission status report
    Date recommendation issued 2007-08-16 Recommendation and reasons
    Recommendation List with criteria/condition

  242. Velaglucerase alfa

    Brand name VPRIV
    Manufacturer Shire Human Genetic Therapies
    Indication Gaucher Disease
    Submission type Initial
    Project Number S0215
    Date submission received 2010-10-29
    Patient input deadline 2010-11-18
    Status Complete Submission status report
    Date recommendation issued 2011-04-25 Recommendation and reasons
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

  243. Voriconazole

    Brand name VFEND
    Manufacturer Pfizer Canada Inc.
    Indication Candidemia
    Submission type Resubmission #2
    Project Number S0056
    Date submission received 2006-03-24
    Status Complete Submission status report
    Date recommendation issued 2006-10-25 Recommendation and reasons
    Recommendation List with criteria/condition

  244. Voriconazole

    Brand name VFEND
    Manufacturer Pfizer Canada Inc.
    Indication Aspergillosis, invasive
    Submission type Resubmission #1
    Project Number S0023
    Date submission received 2004-10-25
    Status Complete Submission status report
    Date recommendation issued 2005-04-14 Recommendation and reasons
    Recommendation List with criteria/condition

  245. Voriconazole

    Brand name VFEND
    Manufacturer Pfizer Canada Inc.
    Indication Aspergillosis, Invasive
    Submission type Initial
    Project Number S0020
    Date submission received 2004-08-24
    Status Withdrawn Submission status report
    Recommendation

  246. Ziprasidone hydrochloride

    Brand name Zeldox
    Manufacturer Pfizer Canada Inc.
    Indication Schizophrenia and related psychotic disorders
    Submission type Initial
    Project Number S0124
    Date submission received 2008-01-10
    Status Complete Submission status report
    Date recommendation issued 2008-08-14 Recommendation and reasons
    Recommendation List with criteria/condition

  247. Zoledronic acid

    Brand name Aclasta
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Osteoporosis (postmenopausal women)
    Submission type Request for Advice
    Project Number S0242
    Date submission received 2011-07-20
    Status Complete Submission status report
    Date recommendation issued 2011-11-16 Recommendation and reasons
    Recommendation List with criteria/condition

  248. Zoledronic acid

    Brand name Aclasta
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication Osteoporosis (postmenopausal women)
    Submission type Initial
    Project Number S0114
    Date submission received 2007-11-29
    Status Complete Submission status report
    Date recommendation issued 2008-06-25 Recommendation and reasons
    Recommendation List with criteria/condition